EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Any role for adjuvant chemotherapy in advanced-stage borderline ovarian tumors? A case report and review of the literature

Jasmine Corti, Tommaso Bianchi, Marta Jaconi, Giorgia Pecis Cavagna, Teresa Aiolfi, Tommaso Grassi, Gaetano Trezzi, Stefania Chiari, Alessandra Casiraghi, Andrea Alberto Lissoni, Robert Fruscio

Frontiers in Oncology · 12.11.2026 · 16

DOI: 10.3389/fonc.2026.1822209 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 12.11.2026. Verfasst von Jasmine Corti und 10 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Borderline ovarian tumors (BOTs) typically affect young women; therefore, fertility preservation is a major concern in their management. Fertility-sparing surgery (FSS) is considered the standard of care for BOTs, regardless of disease stage. However, its oncologic safety remains debated, and the role of chemotherapy in this setting is still unclear. Case presentation We present the case of a 37-year-old woman diagnosed with a FIGO stage IIIB micropapillary borderline ovarian tumor involving both ovaries, with invasive implants on the surface of the right ovary and fallopian tube, as well as diffuse non-invasive desmoplastic implants at other peritoneal sites. The patient underwent debulking fertility-sparing surgery (FSS), resulting in pelvic residual disease (RD). Given the advanced stage, histopathologic features, and the patient’s reproductive goals, six cycles of adjuvant carboplatin chemotherapy were administered. After the patient decided not to pursue further fertility preservation, completion surgery was performed, revealing a complete pathological response with no microscopic RD.

Conclusions

This case illustrates an advanced-stage micropapillary serous BOT in which complete pathological response was obtained after upfront FSS and adjuvant carboplatin chemotherapy. This outcome is noteworthy and hypothesis-generating, as the benefit of chemotherapy in this setting remains controversial in the literature.

Zitieren

APA

Corti, J., Bianchi, T., Jaconi, M., Cavagna, G. P., Aiolfi, T., Grassi, T., Trezzi, G., Chiari, S., Casiraghi, A., Lissoni, A. A., & Fruscio, R. (2026). Any role for adjuvant chemotherapy in advanced-stage borderline ovarian tumors? A case report and review of the literature. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1822209

Vancouver

Corti J, Bianchi T, Jaconi M, Cavagna GP, Aiolfi T, Grassi T, et al. Any role for adjuvant chemotherapy in advanced-stage borderline ovarian tumors? A case report and review of the literature. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1822209

BibTeX
@article{Corti2026,
  author = {Corti, Jasmine and Bianchi, Tommaso and Jaconi, Marta and Cavagna, Giorgia Pecis and Aiolfi, Teresa and Grassi, Tommaso and Trezzi, Gaetano and Chiari, Stefania and Casiraghi, Alessandra and Lissoni, Andrea Alberto and Fruscio, Robert},
  title = {Any role for adjuvant chemotherapy in advanced-stage borderline ovarian tumors? A case report and review of the literature},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1822209}
}
Kostenlos starten →